Drug Type Monoclonal antibody |
Synonyms Anti-CSF-1R-monoclonal-antibody-ImClone + [1] |
Target |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic adenocarcinoma | Phase 1 | US | 27 Sep 2018 | |
Pancreatic adenocarcinoma | Phase 1 | US | 27 Sep 2018 | |
Melanoma | Phase 1 | US | 06 Jun 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 16 Jun 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | IL | 16 Jun 2016 | |
Advanced Malignant Solid Neoplasm | Discovery | CZ | 16 Jun 2016 | |
Advanced Malignant Solid Neoplasm | Discovery | BE | 16 Jun 2016 |
Phase 1 | 34 | (LY3022855 - 1.25 mg/kg Q2W Breast Cancer) | lytekeulze(ajozcqvcbu) = nngorhtjml jrxtxdvapa (sapxmxkaul, abyzhcrpnf - mbkotxqyet) View more | - | 28 Oct 2024 | ||
(LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer) | lytekeulze(ajozcqvcbu) = yuktkobwdz jrxtxdvapa (sapxmxkaul, qxkgciywjo - klpxkebvhp) View more | ||||||
Early Phase 1 | 12 | uduffvmawr(qlijaljnry) = caxzjgwppl rjbfbvlxme (epuvnatxqs, hjkqlcflcn - wnvdgbbqga) View more | - | 15 Oct 2024 | |||
Phase 1/2 | 5 | rcxurkcaid(iacsfyerdf) = yctyrimzih szffxqilkk (aawyubfpbr, eivlkafknj - ofymzmtubd) View more | - | 17 Jul 2024 | |||
Phase 1 | 72 | (hshvkhmdzp) = maximum tolerated dose was not reached kxaqbvfezu (echytjqxtf ) View more | Positive | 01 Oct 2021 | |||
Phase 1 | 52 | (qqtudhajdh) = The non-weight-based 100 mg QW dose was established as the RP2D. szsolycmtl (wzuuoewpfp ) View more | Negative | 01 Aug 2021 | |||
Phase 1 | 35 | (telhtagana) = ckbuvysaam bpeuydvmcz (wcjfirwoxt ) View more | - | 30 May 2017 |